Small Business Programs

Overview 

The Research Need 

Addressing the current overdose crisis requires an all-hands-on-deck approach from all segments of the research community, including private enterprises. Funding from the Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative®, is available to eligible U.S. small businesses as part of the NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs to provide science- and research-based solutions for the evolving opioid and pain public health challenges. 

About the Program 

The goal of NIH-funded SBIR/STTR programs is to encourage private-sector commercialization of technology and to increase small business participation in federally funded research and development activities. HEAL-funded SBIR/STTR projects focus specifically on developing innovative and commercializable technologies and products to prevent, diagnose, and treat opioid use disorder and overdose, as well as to enhance pain management. 

Research includes development of small molecules, antibodies, gene therapy, therapeutic and diagnostic devices, assays, and other technologies. Also of interest are projects developing digital health products, pain models, research tools, health information technology, as well as education/training-focused products and services.  

Open Funding Opportunities

2023
HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management (SB1 Clinical Trial Not Allowed)
Jan 03, 2023
2022
HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)
Sep 15, 2022
2022
HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)
Sep 15, 2022

Program Details

To date, through the NIH HEAL Initiative, NIH has contributed $93.4 million through to fund this program.

Research Examples

Research examples supported by this program include: 

  • Developing instruments to measure the functional impact of chronic pain  
  • Creating a noninvasive brain stimulation strategy to treat addiction 
  • Developing a rapid screening, point-of-care test for neonatal infants 
  • Designing and optimizing novel, peripherally restricted peptide agonists for receptors involved in pain signaling 

  • Arrevus, Inc. – North Carolina 
  • Beacon Tech, Inc. – Maryland 
  • Emitech, Inc. – Massachusetts  
  • Hillmed, Inc. – Texas 
  • Mindlight, LLC – Massachusetts  
  • Olfax, LLC – North Carolina 
  • Opalgenix, Inc. – Indiana 
  • Opio Connect, Inc. – Montana  
  • Public Health Management Corporation – Pennsylvania 
  • Relate XR LLC – Indiana 
  • We the Village, Inc. – New York 

2024
Developing a novel epigenetic regulator as a treatment for opioid use disorder
Nov 05, 2024
2024
Development of a Novel Calcium Channel Therapeutic for Opioid Use Disorder
Nov 05, 2024
2024
NX90: A Treatment for Overdose Caused by High Potency Opioids
Nov 05, 2024
2024
Fast-track: Scalable digital delivery of evidence-based training for addiction professionals to maximize treatment admission and retention rates of opioid use disorder in affected families
Nov 05, 2024
2024
Xylazine and opioid overdose mitigation therapy using decoy receptor biomimetic nanoparticles, NarcoBond platform
Nov 05, 2024

Stay Connected

Stay up to date on the latest HEAL Initiative research advances by subscribing to receive HEAL content directly to your inbox.

Subscribe